Analyzing gender and racial effects of digoxin vs diltiazem in atrial fibrillation mortality using large EHR data

Shrieraam Sathyanarayanan, William Paiva

Research output: Contribution to journalArticle

Abstract

Digoxin is an atrial fibrillation (AF) rate control drug that is still in use. New randomized trial data comparing digoxin with other agents is unlikely to become available, but observational data exists in the form of large patient databases. We compared the mortality rates between Digoxin and Diltiazem using the Cerner Healthfacts Data. The study was performed on data with 52,775 U.S. patients with atrial fibrillation. The goal of the study was to assess the mortality versus survival rates between patients. Patients’ characteristics were reviewed among those receiving either a calcium channel antagonist (diltiazem) or digoxin. The mortality rates for patients who took digoxin were greater than that of patients who took diltiazem and had 1.31 times the risk of mortality [5.23% vs 3.98%, RR 1.31, CI 1.21-1.42, p < 0.001]. African Americans had the highest mortality rate compared to other races [6.28%, p<0.0001]. The age (in years) of patients treated with digoxin was higher than that of patients treated with diltiazem [74.96 vs 68.45, p<0.0001]. Length of stay (in days) of patients with digoxin was also significantly higher than that of diltiazem patients [74.96 vs 68.45, p<0.0001; 5.95 vs 4.99, p<0.0001]. Within certain races, digoxin mortality rates were higher between male and female patients. The mortality rate differences show adverse outcomes and increased risk of mortality was found in patients taking digoxin.
Original languageAmerican English
JournalOklahoma State Medical Proceedings
Volume1
Issue number4
StatePublished - 2019

Fingerprint

Diltiazem
Digoxin
Atrial Fibrillation
Mortality
Drug and Narcotic Control
Calcium Channel Blockers
African Americans
Length of Stay
Survival Rate
Databases

Keywords

  • Atrial fibrillation mortality
  • digoxin vs diltiazem
  • Atrial fibrillation EHR data
  • gender and racial effects in atrial fibrillation
  • digoxin moratlity
  • digoxin and diltiazem in atrial fibrillation
  • digitalis in atrial fibrillation

Cite this

@article{487dfa9ffda140ec8936bea17443a70e,
title = "Analyzing gender and racial effects of digoxin vs diltiazem in atrial fibrillation mortality using large EHR data",
abstract = "Digoxin is an atrial fibrillation (AF) rate control drug that is still in use. New randomized trial data comparing digoxin with other agents is unlikely to become available, but observational data exists in the form of large patient databases. We compared the mortality rates between Digoxin and Diltiazem using the Cerner Healthfacts Data. The study was performed on data with 52,775 U.S. patients with atrial fibrillation. The goal of the study was to assess the mortality versus survival rates between patients. Patients’ characteristics were reviewed among those receiving either a calcium channel antagonist (diltiazem) or digoxin. The mortality rates for patients who took digoxin were greater than that of patients who took diltiazem and had 1.31 times the risk of mortality [5.23{\%} vs 3.98{\%}, RR 1.31, CI 1.21-1.42, p < 0.001]. African Americans had the highest mortality rate compared to other races [6.28{\%}, p<0.0001]. The age (in years) of patients treated with digoxin was higher than that of patients treated with diltiazem [74.96 vs 68.45, p<0.0001]. Length of stay (in days) of patients with digoxin was also significantly higher than that of diltiazem patients [74.96 vs 68.45, p<0.0001; 5.95 vs 4.99, p<0.0001]. Within certain races, digoxin mortality rates were higher between male and female patients. The mortality rate differences show adverse outcomes and increased risk of mortality was found in patients taking digoxin.",
keywords = "Atrial fibrillation mortality, digoxin vs diltiazem, Atrial fibrillation EHR data, gender and racial effects in atrial fibrillation, digoxin moratlity, digoxin and diltiazem in atrial fibrillation, digitalis in atrial fibrillation",
author = "Shrieraam Sathyanarayanan and William Paiva",
year = "2019",
language = "American English",
volume = "1",
journal = "Oklahoma State Medical Proceedings",
issn = "2475-8914",
number = "4",

}

TY - JOUR

T1 - Analyzing gender and racial effects of digoxin vs diltiazem in atrial fibrillation mortality using large EHR data

AU - Sathyanarayanan, Shrieraam

AU - Paiva, William

PY - 2019

Y1 - 2019

N2 - Digoxin is an atrial fibrillation (AF) rate control drug that is still in use. New randomized trial data comparing digoxin with other agents is unlikely to become available, but observational data exists in the form of large patient databases. We compared the mortality rates between Digoxin and Diltiazem using the Cerner Healthfacts Data. The study was performed on data with 52,775 U.S. patients with atrial fibrillation. The goal of the study was to assess the mortality versus survival rates between patients. Patients’ characteristics were reviewed among those receiving either a calcium channel antagonist (diltiazem) or digoxin. The mortality rates for patients who took digoxin were greater than that of patients who took diltiazem and had 1.31 times the risk of mortality [5.23% vs 3.98%, RR 1.31, CI 1.21-1.42, p < 0.001]. African Americans had the highest mortality rate compared to other races [6.28%, p<0.0001]. The age (in years) of patients treated with digoxin was higher than that of patients treated with diltiazem [74.96 vs 68.45, p<0.0001]. Length of stay (in days) of patients with digoxin was also significantly higher than that of diltiazem patients [74.96 vs 68.45, p<0.0001; 5.95 vs 4.99, p<0.0001]. Within certain races, digoxin mortality rates were higher between male and female patients. The mortality rate differences show adverse outcomes and increased risk of mortality was found in patients taking digoxin.

AB - Digoxin is an atrial fibrillation (AF) rate control drug that is still in use. New randomized trial data comparing digoxin with other agents is unlikely to become available, but observational data exists in the form of large patient databases. We compared the mortality rates between Digoxin and Diltiazem using the Cerner Healthfacts Data. The study was performed on data with 52,775 U.S. patients with atrial fibrillation. The goal of the study was to assess the mortality versus survival rates between patients. Patients’ characteristics were reviewed among those receiving either a calcium channel antagonist (diltiazem) or digoxin. The mortality rates for patients who took digoxin were greater than that of patients who took diltiazem and had 1.31 times the risk of mortality [5.23% vs 3.98%, RR 1.31, CI 1.21-1.42, p < 0.001]. African Americans had the highest mortality rate compared to other races [6.28%, p<0.0001]. The age (in years) of patients treated with digoxin was higher than that of patients treated with diltiazem [74.96 vs 68.45, p<0.0001]. Length of stay (in days) of patients with digoxin was also significantly higher than that of diltiazem patients [74.96 vs 68.45, p<0.0001; 5.95 vs 4.99, p<0.0001]. Within certain races, digoxin mortality rates were higher between male and female patients. The mortality rate differences show adverse outcomes and increased risk of mortality was found in patients taking digoxin.

KW - Atrial fibrillation mortality

KW - digoxin vs diltiazem

KW - Atrial fibrillation EHR data

KW - gender and racial effects in atrial fibrillation

KW - digoxin moratlity

KW - digoxin and diltiazem in atrial fibrillation

KW - digitalis in atrial fibrillation

M3 - Article

VL - 1

JO - Oklahoma State Medical Proceedings

JF - Oklahoma State Medical Proceedings

SN - 2475-8914

IS - 4

ER -